Real-world use of difelikefalin in hemodialysis patients at a large dialysis organization in the United States: a retrospective database study
Abstract Background Chronic kidney disease–associated pruritus (CKD-aP) can negatively impact quality of life and survival among patients receiving maintenance hemodialysis. Difelikefalin, a selective κ-opioid receptor agonist, is the first medication approved for treatment of moderate-to-severe CKD...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-025-04074-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|